Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy

Autor: Nassim Kamar, René Gerolami, Jenny Herrod, Jean-Marie Péron, Jacques Izopet, Brendan McLean, David H. Benninger, Baziel G.M. van Engelen, Johannes Hartl, Roland Sahli, P. Ripellino, Mohamed Abdelrahim, Vincent Aubert, Marcus Panning, Rebecca Lissmann, Emanuela Pasi, Hélène Blasco-Perrin, Hafiz Hamad Ashraf, Nan X. Lin, Richard P. Bendall, Richard G. Madden, Shahram Attarian, Nens van Alfen, Jeroen J.J. van Eijk, Sven Pischke, Harry R. Dalton, Bart C. Jacobs, Omar A.B.A.L. Masri, Maria Teresa Giordani, Philippe Colson, Darius Moradpour, Montserrat Fraga, Giorgia Melli, Miriam Fritz, Claudio Gobbi, Thierry Kuntzer, Catherine Jones

Publikováno v: Neurology
Neurology, American Academy of Neurology, 2017, 89 (9), pp.909-917. ⟨10.1212/WNL.0000000000004297⟩
Neurology, 89, 909-917
Neurology, 2017, 89 (9), pp.909-917. ⟨10.1212/WNL.0000000000004297⟩
Neurology, 89, 9, pp. 909-917
Neurology, 89(9), 909-917. Lippincott Williams & Wilkins

Objective:To determine the clinical phenotype and outcome in hepatitis E virus–associated neuralgic amyotrophy (HEV-NA).Methods:Cases of NA were identified in 11 centers from 7 European countries, with retrospective analysis of demographics, clinic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe36fb8d62f43284317c6da449667767
https://pubmed.ncbi.nlm.nih.gov/28768846